All lobbying filings

DLA PIPER LLP (US)

DLA PIPER LLP (US) filed a Q2 report for BIOGEN, INC. on July 20, 2026, reporting $60,000 in lobbying income.

Lobbying for BIOGEN, INC. · Biotechnology company.

All filings by DLA PIPER LLP (US) · Everything BIOGEN, INC. has reported

Filing · LD-2 quarterly report Q2 report

Reporting period

2nd Quarter 2026

Apr 1 - June 30 · Posted Jul 20, 2026

Income

$60,000

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Government bodies contacted 4

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 6

Pharmacy

Issues relating to drug pricing policy. Pharmacy benefit manager legislation related to patient access to therapies.

Intellectual property protections and enforcement. Biopharmaceutical patent policy.

Health Issues

Issues related to rare diseases including Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), Lou Gehrig's Disease. Drug pricing and drug development policies. Screening and diagnosis. Patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues. Orphan Drug Act. Issues related to the FDA including PDUFA, drug reviews, approval pathways, and clinical trials. Policies related to value based arrangements. Issues related to the 340B program.

Medical/Disease Research/Clinical Labs

Issues related to rare disease and treatment. Drug pricing policy. Public policy around patients' access and affordability. Alzheimer's disease. Issues related to Medicare Part B and D.

Taxation/Internal Revenue Code

Issues related to tax reform.

Trade (domestic/foreign)

Trade-related public policy around tariffs and intellectual property.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.